Durvalumab
Treatment for Tracheal Bronchus And Lung Cancer
Typical Dosage: 10 mg/kg IV every 2 weeks or 1500 mg IV every 4 weeks
Effectiveness
80%
Safety Score
35%
Clinical Trials
300
Participants
25K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
35
DangerousModerateSafe
Treatment Details
Dosage Range
10 mg/kg IV every 2 weeks or 1500 mg IV every 4 weeks
Time to Effect
2-4 months
Treatment Duration
Up to 1 year for Stage III consolidation, or until disease progression/unacceptable toxicity
Evidence Quality
HIGHConfidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$140,000
Monitoring:$8,000
Side Effect Mgmt:$10,000
Total Annual:$158,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$60,000/QALY
QALYs Gained
1.62
Outcome-Based Costs
Cost per Responder
$526,667
Cost per Remission
$3,160,000
Comparison vs Placebo/Active Surveillance
Cost Difference
+$140,000/year
More expensive
QALY Difference
+1.62 QALYs
Better outcomes
Dominance
No dominance
Durvalumab Outcomes
for Tracheal Bronchus And Lung Cancer
Efficacy Outcomes
Overall Effectiveness
+80%
Response Rate
+30%
Remission Rate
+5%
Common Side Effects
Cough
+30%
Fatigue
+30%
Dyspnea
+20%
Radiation pneumonitis
+15%
Diarrhea
+15%
Rash
+10%
Hypothyroidism
+10%
Sources:
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov